AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (Currently Amended) A pharmaceutical composition comprising micronized fenofibrate, a surfactant, and a binding cellulose derivative as a solubilization adjuvant, wherein said fenofibrate is present in an amount greater than or equal to 60% by weight, relative to the weight of the composition, and further wherein said binding cellulose derivative represents between 2 to 15% by weight, relative to the weight of the composition.
- 2. (Previously Presented) The composition of claim 1, wherein said binding cellulose derivative is hydroxypropylmethylcellulose.
- 3. (Previously Presented) The composition of claim 2, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 18 cP.
- 4. (Previously Presented) The composition of claim 1, wherein said fenofibrate is present in an amount greater than or equal to 70% by weight, relative to the weight of the composition.

- 5. (Previously Presented) The composition of claim 1, wherein said surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monooleate, sorbitan monododecanoate, and sodium lauryl sulfate.
- 6. (Previously Presented) The composition of claim 1, wherein said surfactant represents between 1 and 10% by weight, relative to the weight of the fenofibrate.
- 7. (Previously Presented) The composition of claim 2, wherein said fenofibrate/HPMC mass ratio is between 5/1 and 15/1.
- 8. Cancelled.
- 9. (Previously Presented) The composition of claim 1, wherein said composition further comprises at least one excipient.
- 10. (Previously Presented) The composition of claim 1, wherein said micronized fenofibrate has a mean particle size less than 15 μm.
- 11. (Currently Amended) The composition of claim 1, wherein said composition is in the form of [gelatin capsules containing] powder or granules, optionally contained in gelatin capsules.

- 12. (Previously Presented) A method for preparing the composition of claim 11, wherein said granules are prepared by assembly on neutral microgranules, by spraying an aqueous suspension containing the surfactant, the solubilized binding cellulose derivative and the micronized fenofibrate in suspension.
- 13. (Currently Amended) The method for preparing the composition of claim 11, wherein said granules are obtained by wet granulation of powder, according to which the constituents, including in particular the micronized fenofibrate, the surfactant and the <u>binding</u> cellulose derivative, are granulated by wet granulation using an aqueous wetting solution, dried and calibrated.
- 14. (Previously Presented) The composition of claim 3, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 3.6 cP.
- 15. (Previously Presented) The composition of claim 1, wherein said fenofibrate is present in an amount greater than or equal to 75% by weight, relative to the weight of the composition.
- 16. (Previously Presented) The composition of claim 1, wherein said surfactant represents between 3 and 5% by weight, relative to the weight of the fenofibrate.
- 17. (Previously Presented) The composition of claim 1, wherein said binding cellulose derivative represents between 5 and 12% by weight, relative to the weight of the composition.

- 18. (Previously Presented) The composition of claim 9, wherein said excipient is selected from the group consisting of a diluent, an antifoaming agent, a lubricant, and a mixture thereof.
- 19. (Previously Presented) The composition of claim 9, wherein said excipient is selected from the group consisting of lactose, α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)], a mixture of α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)] with silicon dioxide, and talc.
- 20. (Previously Presented) The composition of claim 1, wherein said micronized fenofibrate has a mean particle size less than 8 μm.
- 21. (New) A pharmaceutical composition comprising micronized fenofibrate, a surfactant, and a binding cellulose derivative as a solubilization agent, wherein the mass ratio of fenofibrate to binding cellulose derivative is between 5/1 and 15/1.
- 22. (New) The pharmaceutical composition according to claim 21, wherein the binding cellulose derivative is hydroxypropylmethylcellulose.
- 23. (New) The composition of claim 21, wherein said binding cellulose derivative has an apparent viscosity of between 2.4 and 18 cP.

- 24. (New) The composition of claim 21, wherein said binding cellulose derivative has an apparent viscosity of between 2.4 and 3.6 cP.
- 25. (New) The composition of claim 21, wherein said surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monooleate, sorbitan monododecanoate, and sodium lauryl sulfate.
- 26. (New) The composition of claim 21, wherein said surfactant represents between 1 and 10% by weight, relative to the weight of fenofibrate.
- 27. (New) The composition of claim 21, wherein said surfactant represents between 3 and 5% by weight, relative to the weight of fenofibrate.
- 28. (New) The composition of claim 21, wherein said composition further comprises at least one excipient.
- 29. (New) The composition of claim 28, wherein said excipient is selected from the group consisting of a diluent, an antifoaming agent, a lubricant, and a mixture thereof.
- 30. (New) The composition of claim 29, wherein said diluent is lactose.

- 31. (New) The composition of claim 29, wherein said antifoaming agent is α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)] or a mixture of α -(trimethylsilyl)- ω -methylpoly[oxy-(dimethylsilylene)] with silicon dioxide.
- 32. (New) The composition of claim 29, wherein said lubricant is talc.
- 33. (New) The composition of claim 21, wherein said micronized fenofibrate has a mean particle size less than 15 μ m.
- 34. (New) The composition of claim 21, wherein said micronized fenofibrate has a mean particle size less than 8 μ m.
- 35. (New) The composition of claim 21, wherein said composition is in the form of granules or powder, optionally contained in gelatin capsules.
- 36. (New) A method for preparing the composition of claim 35, wherein said granules are prepared by assembly on neutral microgranules, by spraying an aqueous suspension containing the surfactant, solubilized binding cellulose derivative, and the micronized fenofibrate in suspension.
- 37. (New) A method for preparing the composition of claim 35, wherein said granules are obtained by wet granulation of powder, wherein the constituents, including the micronized fenofibrate, the surfactant, and binding cellulose derivative,

are granulated by wet granulation using an aqueous wetting solution, dried, and calibrated.

- 38. (New) An aqueous suspension containing micronized fenofibrate in suspension, a solubilized binding cellulose derivative, and a surfactant, wherein the mass ratio of said fenofibrate to binding cellulose derivative is between 5/1 and 15/1.
- 39. (New) The suspension according to claim 38, wherein said binding cellulose derivative is hydroxypropylmethylcellulose.
- 40. (New) The suspension according to claim 39, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 18 cP.
- 41. (New) The suspension according to claim 39, wherein said hydroxypropylmethylcellulose has an apparent viscosity of between 2.4 and 3.6 cP.
- 42. (New) The suspension according to claim 38, wherein said surfactant is selected from the group consisting of polyoxyethylene 20 sorbitan monooleate, sorbitan monododecanoate, and sodium lauryl sulfate.
- 43. (New) The suspension according to claim 38, wherein said surfactant represents between 1 and 10% by weight, relative to the weight of fenofibrate.

- 44. (New) The suspension according to claim 38, wherein said micronized fenofibrate has a mean particle size less than 15 μ m.
- 45. (New) The suspension according to claim 38, wherein said micronized fenofibrate has a mean particle size less than 8 μ m.
- 46. (New) A method of preparing granules of fenofibrate, comprising the step of spraying the suspension according to claim 38 onto neutral microgranules.